Daniel Schramek
Overview
Explore the profile of Daniel Schramek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
3167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kim H, Aliar K, Tharmapalan P, McCloskey C, Kuttanamkuzhi A, Grunwald B, et al.
Cell Rep
. 2023 Oct;
42(11):113382.
PMID: 37883228
No abstract available.
12.
Kim H, Aliar K, Tharmapalan P, McCloskey C, Kuttanamkuzhi A, Grunwald B, et al.
Cell Rep
. 2023 Oct;
42(10):113256.
PMID: 37847590
It is widely assumed that all normal somatic cells can equally perform homologous recombination (HR) and non-homologous end joining in the DNA damage response (DDR). Here, we show that the...
13.
Panzeri I, Fagnocchi L, Apostle S, Tompkins M, Wolfrum E, Madaj Z, et al.
bioRxiv
. 2023 Sep;
PMID: 37745326
DNA mutations are necessary drivers of cancer, yet only a small subset of mutated cells go on to cause the disease. To date, the mechanisms that determine which rare subset...
14.
Dong W, Fekete A, Chen X, Liu H, Beilhartz G, Chen X, et al.
Nat Cancer
. 2023 Sep;
4(10):1418-1436.
PMID: 37697045
Glioblastoma (GBM) is an incurable brain cancer that lacks effective therapies. Here we show that EAG2 and Kvβ2, which are predominantly expressed by GBM cells at the tumor-brain interface, physically...
15.
Dervovic D, Malik A, Chen E, Narimatsu M, Adler N, Afiuni-Zadeh S, et al.
Nat Commun
. 2023 Sep;
14(1):5404.
PMID: 37670013
No abstract available.
16.
Dervovic D, Malik A, Chen E, Narimatsu M, Adler N, Afiuni-Zadeh S, et al.
Nat Commun
. 2023 May;
14(1):3150.
PMID: 37258521
How the genetic landscape governs a tumor's response to immunotherapy remains poorly understood. To assess the immune-modulatory capabilities of 573 genes associated with altered cytotoxicity in human cancers, here we...
17.
Schramek D, Kotsinas A, Meixner A, Wada T, Elling U, Pospisilik J, et al.
Nat Genet
. 2023 Apr;
55(5):891.
PMID: 37059914
No abstract available.
18.
McLean B, Istadi A, Clack T, Vankan M, Schramek D, Neely G, et al.
Adv Genet (Hoboken)
. 2023 Mar;
3(4):2200014.
PMID: 36911295
Cancer is the second leading cause of death globally, with therapeutic resistance being a major cause of treatment failure in the clinic. The dynamic signaling that occurs between tumor cells...
19.
Yan Y, Gauthier M, Malik A, Fotiadou I, Ostrovski M, Dervovic D, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765696
Receptor-interacting serine/threonine protein kinase 4 (RIPK4) and its kinase substrate the transcription factor interferon regulatory factor 6 (IRF6) play critical roles in the development and maintenance of the epidermis. In...
20.
Vujovic A, de Rooij L, Keyvani Chahi A, Chen H, Yee B, Loganathan S, et al.
Blood Cancer Discov
. 2023 Feb;
4(3):180-207.
PMID: 36763002
Significance: LSC-targeted therapies remain a significant unmet need in AML. We developed a stem-cell-adapted in vivo CRISPR screen to identify key LSC drivers. We uncover widespread RNA-binding protein dependencies in...